Amgen's most recent trend suggests a bullish bias. One trading opportunity on Amgen is a Bull Put Spread using a strike $165.00 short put and a strike $160.00 long put offers a potential 14.16% return on risk over the next 15 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $165.00 by expiration. The full premium credit of $0.62 would be kept by the premium seller. The risk of $4.38 would be incurred if the stock dropped below the $160.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Amgen is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Amgen is bullish.
The RSI indicator is at 77.66 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
Novartis copy of Amgen biotech drug shows similar efficacy-study
Mon, 08 Dec 2014 08:53:20 GMT
Reuters – Novartis said its copycat version of Amgen's Neupogen for patients with low white blood cell counts works as well as the original drug in a late-stage trial. The medicine, made by Novartis' generics arm …
12:02 am Amgen and Onyx (ONXX) announce detailed results from phase 3 Aspire study Of Kyprolis in patients with relapsed multiple myeloma; Overall response rate, duration of response, Health-related quali
Mon, 08 Dec 2014 05:02:00 GMT
Amgen Announces New Data from Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study in Patients with Acute Lymphoblastic Leukemia and Minimal Residual Disease
Sun, 07 Dec 2014 05:15:22 GMT
noodls – This is an abstract of the original noodl. To continue reading this document, click here for the original version.
Amgen Announces New Data From Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease
Sat, 06 Dec 2014 18:26:11 GMT
noodls – THOUSAND OAKS, Calif., Dec. 6, 2014 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced new data from the Phase 2 BLAST study which evaluated the bispecific T cell engager (BiTE®) immunotherapy BLINCYTO™ …
Amgen Announces New Data From Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease
Sat, 06 Dec 2014 18:00:00 GMT
PR Newswire – THOUSAND OAKS, Calif., Dec. 6, 2014 /PRNewswire/ — Amgen (AMGN) today announced new data from the Phase 2 BLAST study which evaluated the bispecific T cell engager (BiTE®) immunotherapy BLINCYTO™ (blinatumomab) in patients with minimal residual disease (MRD) positive B-cell precursor acute lymphoblastic leukemia (ALL). In the study, 78 percent of patients who received BLINCYTO experienced a complete MRD response (95 percent CI: 69-85 percent), a measure of eradication of residual disease at the molecular level, after one treatment cycle. “BLINCYTO is the most advanced of Amgen's BiTE® immunotherapies, a new and innovative approach that helps the body's own immune system fight cancer,” said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.
Related Posts
Also on Market Tamer…
Follow Us on Facebook